Gideon M. Blumenthal, MD
Richard Pazdur, MD, Director of the Oncology Center of Excellence and Office of Hematology and Oncology Products (OHOP) Acting Director, has announced the appointment of Gideon M. Blumenthal, MD, as Acting Deputy Office Director of the OHOP at the U.S. Food and Drug Administration (FDA).
Dr. Blumenthal is a medical oncologist and serves as OHOP’s Associate Director of Precision Therapeutics. He is board-certified in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine.
Other Roles
Dr. Blumenthal serves as the OHOP scientific liaison to ASCO, is a member of the Foundation for the National Institutes of Health Biomarkers Consortium Steering Committee, and served on the White House Cancer Moonshot committee collaborating with the Blood Profiling Atlas in Cancer, a consortium launched to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. His research has focused on investigating novel intermediate endpoints and biomarkers to better inform oncology drug and diagnostic development and clinical trial design.
Dr. Blumenthal earned his medical degree from the University of Maryland School of Medicine. He completed an internal medicine residency at University of Maryland, followed by a hematology/oncology fellowship at the National Cancer Institute (NCI).
Dr. Blumenthal previously worked as Medical Officer, Clinical Team Leader (thoracic oncology and head and neck cancer), and Scientific Liaison (lung cancer) at the FDA. He was an Associate Investigator on several phase I and II clinical trials as a fellow, and then an Adjunct Attending Physician in the thoracic malignancy branch of the NCI.
Amy E. McKee, MD, who served as Acting Deputy Office Director since December 2015, will continue to develop and support OHOP strategic policy initiatives and research efforts as a Supervisory Associate Director. ■
